Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901101 | 1.00 | MAPK1 (0.56) | MAPK1TSHRKDM4EALDH1A1TDP1 | |
| SCHEMBL2609782 | 1.00 | MAPK1 (0.56) | MAPK1TSHRKDM4EALDH1A1TDP1 | |
| SCHEMBL20089291 | 0.91 | MAPK1 (0.48) | MAPK1TSHRKDM4EALDH1A1TDP1 | |
| SCHEMBL1982314 | 0.86 | MAPK1 (0.65) | MAPK1TSHRKDM4EALDH1A1TDP1 | |
| SCHEMBL6669573 | 0.83 | MAPK1 (0.45) | MAPK1TSHR | |
| SCHEMBL18027553 | 0.82 | MAPK1 (0.54) | MAPK1KDM4EALDH1A1TDP1 | |
| SCHEMBL1927186 | 0.82 | MAPK1 (0.54) | MAPK1KDM4EALDH1A1TDP1 | |
| SCHEMBL18027532 | 0.82 | MAPK1 (0.54) | MAPK1KDM4EALDH1A1TDP1 | |
| SCHEMBL1927183 | 0.82 | MAPK1 (0.54) | MAPK1KDM4EALDH1A1TDP1 | |
| SCHEMBL14649738 | 0.82 | MAPK1 (0.37) | MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11773086-B2 | Fungal modulators | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9388112-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-9388112-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-04 | — | — | US | disclosed |
| US-20130131167-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-23 | — | — | US | disclosed |
| US-20130131167-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-23 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | MAPK1 3668/4885TSHR 2922/4885KDM4E 502/4885 |
| US-11773086-B2 | Fungal modulators | ABCB11, ABCB1, ABCC1 | MAPK1 1871/4885TSHR 4863/4885KDM4E 3443/4885 |
| US-20180111932-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | SCN1B, SCN3A, SCN5A | MAPK1 1375/4885TSHR 1271/4885KDM4E 1689/4885 |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | MAPK1 3831/4885TSHR 2717/4885KDM4E 1393/4885 |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | AR, SHBG, ESRRA | MAPK1 4052/4885TSHR 819/4885KDM4E 1402/4885 |
| US-20130131167-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | CYP19A1, AR, SHBG | MAPK1 859/4885TSHR 642/4885KDM4E 2699/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | MAPK1 3668/4885TSHR 2922/4885KDM4E 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.